pentasa- mesalamine capsule
takeda pharmaceuticals america, inc. - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or any components of this medication.
pentasa- mesalamine capsule
avera mckennan hospital - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients who have demonstrated hypersensitivity to mesalamine, any other components of this medication, or salicylates.
pentasa mesalazine 1 g prolonged release tablet blister pack
ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - tablet, modified release - excipient ingredients: magnesium stearate; purified talc; ethylcellulose; povidone; microcrystalline cellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.
pentasa mesalazine 0.5 g prolonged release tablet blister pack
ferring pharmaceuticals pty ltd - mesalazine, quantity: 500 mg - tablet, modified release - excipient ingredients: purified talc; ethylcellulose; povidone; microcrystalline cellulose; magnesium stearate - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.
pentasa mesalazine 4 g prolonged release granules sachet
ferring pharmaceuticals pty ltd - mesalazine, quantity: 4 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.
pentasa mesalazine 2 g prolonged release granules sachet
ferring pharmaceuticals pty ltd - mesalazine, quantity: 2 g - granules, modified release - excipient ingredients: povidone; ethylcellulose - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.
pentasa mesalazine 1 g prolonged release granules sachet
ferring pharmaceuticals pty ltd - mesalazine, quantity: 1 g - granules, modified release - excipient ingredients: ethylcellulose; povidone - treatment of mild to moderate ulcerative colitis and crohn's disease and maintenance of remission.
pentasa mesalazine 1g suppository blister pack
ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - suppository, compressed - excipient ingredients: purified talc; povidone; macrogol 6000; magnesium stearate - treatment of ulcerative procitis.
pentasa mesalazine 1g enema bottle
ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.
pentasa- mesalamine capsule
carilion materials management - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 250 mg - pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis. pentasa is contraindicated in patients who have demonstrated hypersensitivity to mesalamine, any other components of this medication, or salicylates.